Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | PRKACA | P17612 | 1/20 | 0.59 |
| ▸ | GSK3A | P49840 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
| ▸ | PRKX | P51817 | 1/20 | 0.59 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.59 |
| ▸ | MMP13 | P45452 | 3/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4666647 | 0.92 | SLC5A7 (0.54) | ROCK2CYP3A4CYP2D6CYP2C9PRKACA | |
| SCHEMBL4664201 | 0.91 | MMP13 (0.55) | ROCK2CYP3A4CYP2D6CYP2C9PRKACA | |
| SCHEMBL4772536 | 0.90 | SLC5A7 (0.51) | ROCK2CYP3A4CYP2D6CYP2C9PRKACA | |
| SCHEMBL4666649 | 0.90 | SLC5A7 (0.54) | ROCK2CYP3A4CYP2D6CYP2C9PRKACA | |
| SCHEMBL4666621 | 0.89 | ROCK2 (0.60) | ROCK2CYP3A4CYP2D6CYP2C9PRKACA | |
| SCHEMBL4930039 | 0.88 | MAPK14 (0.58) | CYP3A4MMP13MAPK14ALDH1A1KMT2A | |
| SCHEMBL4666224 | 0.88 | ALDH1A1 (0.53) | ROCK2CYP3A4CYP2D6CYP2C9PRKACA | |
| SCHEMBL14026989 | 0.88 | ROCK2 (0.51) | ROCK2CYP3A4CYP2D6CYP2C9PRKACA | |
| SCHEMBL4878514 | 0.88 | SLC5A7 (0.49) | ROCK2CYP3A4CYP2D6CYP2C9PRKACA | |
| SCHEMBL4237034 | 0.88 | SLC5A7 (0.47) | ROCK2CYP3A4CYP2D6CYP2C9PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | claimed |
| EP-1891065-A1 | NOVEL MCHR1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF MCHR1 MEDIATED CONDITIONS AND DISORDERS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | claimed |
| WO-2006130075-A1 | NOVEL MCHR1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF MCHR1 MEDIATED CONDITIONS AND DISORDERS | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | WO | claimed |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| EP-1891065-A1 | NOVEL MCHR1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF MCHR1 MEDIATED CONDITIONS AND DISORDERS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006130075-A1 | NOVEL MCHR1 ANTAGONISTS AND THEIR USE FOR THE TREATMENT OF MCHR1 MEDIATED CONDITIONS AND DISORDERS | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | MCHR1, MCHR2, HCRTR1 | ROCK2 1477/4885CYP3A4 1668/4885CYP2D6 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.